Following its meetings over October 11-14, the European Medicines Agency’s human medicines committee, the CHMP, today recommended five novel medicines and one generic for approval.
The final European Commission decisions on the Marketing Authorization Application for the various drugs is anticipated later in 2021.
US biotech firm Gilead Sciences’ (Nasdaq: GILD) Trodelvy (sacituzumab govitecan) was granted a positive opinion for the treatment of unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze